```
     (FILE 'HOME' ENTERED AT 10:55:00 ON 28 OCT 2003)

     FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 10:55:18 ON 28 OCT 2003
L1        13231 S LACTOFERRIN
L2          260 S L1 AND (ASTHMA OR DIAPER (W) RASH OR CONTACT? (W) DERMATITIS
L3           77 S L2 AND ASTHMA
L4           46 DUPLICATE REMOVE L3 (31 DUPLICATES REMOVED)
L5           30 S L4 AND PY<=1997
L6            1 S L2 AND DIAPER
L7           22 S L2 AND DERMATITIS
L8           11 S L7 AND PY<=1997
L9           11 S L8 NOT L5
L10          11 S L8 NOT L6
L11          15 S L2 AND  PSORIASIS
L12           8 S L11 AND PY<=1997
L13           5 DUPLICATE REMOVE L12 (3 DUPLICATES REMOVED)

=>
```

L4 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:145305 CAPLUS
DOCUMENT NUMBER: 126:162307
TITLE: Topical preparations containing vitamin C derivatives for treatment of skin inflammations and aging
INVENTOR(S): Akyama, Junichi; Yamamoto, Itaru
PATENT ASSIGNEE(S): Kaminomoto Honho Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08333260	A2	19961217	JP 1995-163046	19950606

AB Vitamin C derivs., i.e. ascorbic acid phosphate salts and ascorbic acid glycosides, are effective for the treatment of skin inflammations and prevention of the aging. Topical prepns. may further contain an anti-inflammatory agent selected from the group consisting of indomethacin, glycyrrhizinic acid, glycyrrhetin, aspirin, and mixts. thereof and a lipid peroxide inhibitory agent selected from the group consisting of vitamin E, .beta.-carotene, **lactoferrin**, cactus ext., aloe ext., deferoxamine, BHA, BHT, and transferrin. An emulsion contg. L-ascorbic acid 2-glucoside 4, indomethacin 0.1 %, and other ingredients was formulated.

L4 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1989:619317 CAPLUS
DOCUMENT NUMBER: 111:219317
TITLE: Transdermal preparations containing immunoglobulin A and **lactoferrin** for treatment of **dermatitis**
INVENTOR(S): Okada, Tomio; Tanaka, Hiroshi
PATENT ASSIGNEE(S): Nonogawa Shoji Y. K., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01135726	A2	19890529	JP 1987-292738	19871119
JP 08013754	B4	19960214		

AB Transdermal prepns., which have high selectivity for Staphylococcus aureus and are useful for treatment of bacteria-caused or atopic **dermatitis**, contain secretory component-conjugated IgA and **lactoferrin**. White vaselin 40.0, cetanol 10.0, beeswax 5.0, sorbitan sesquioleate 5.0, Lauromacrogol 0.5, Bu p-hydroxybenzoate 0.01, Me p-hydroxybenzoate 0.01, secretory component-conjugated IgA 0.3, and **lactoferrin** 0.5% by wt. were mixed to give an ointment, which was effective for pyoderma and atopic **dermatitis** in humans.

L4 ANSWER 16 OF 27 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 97147583 MEDLINE
DOCUMENT NUMBER: 97147583 PubMed ID: 8994355
TITLE: Subthreshold UV radiation-induced peroxide formation in cultured corneal epithelial cells: the protective effects of **lactoferrin**.
AUTHOR: Shimmura S; Suematsu M; Shimoyama M; Tsubota K; Oguchi Y; Ishimura Y
CORPORATE SOURCE: Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
SOURCE: EXPERIMENTAL EYE RESEARCH, (1996 Nov) 63 (5) 519-26. Journal code: EPL; 0370707. ISSN: 0014-4835.
PUB. COUNTRY: ENGLAND: United Kingdom
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199701
ENTRY DATE: Entered STN: 19970219
Last Updated on STN: 19970219
Entered Medline: 19970130

AB Acute exposure to suprathreshold ultraviolet B radiation (UV-B) is known to cause photokeratitis resulting from the necrosis and shedding of corneal epithelial cells. however, the corneal effects of low dose UV-B in the environmental range is less clear. In this study, subthreshold UV-B was demonstrated to cause non-necrotic peroxide formation in cultured corneal epithelial cells, which was attenuated by the major tear protein **lactoferrin**. Intracellular oxidative insults and cell viability of rabbit corneal epithelial cells (RCEC) were assessed by dual-color digital microfluorography using carboxydichlorofluorescin (CDCFH) diacetate bis (acetoxymethyl) ester, a hydroperoxide-sensitive fluoroprobe, and propidium iodide (PI), respectively. The magnitude of **UV-induced** oxidative insults was calibrated by concentrations of exogenously applied H2O2 which evoke compatible levels of CDCFH oxidation.

Exposure of RCEC to low-dose UV-B (2.0 mJ cm-2 at 313 nm, 10.0 mJ cm-2 total UV-B) caused intracellular oxidative changes which were equivalent to those elicited by 240 microM hydrogen peroxide under the conditions of the study. The changes were dose dependent, non-necrotic, and were partially inhibited by **lactoferrin** (1 mg ml-1) but not by iron-saturated **lactoferrin**. Pretreatment with deferoxamine (2 mM) or catalase (100 U ml-1) also attenuated the **UV-induced** oxidative stress. The results indicate that UV-B comparable to solar irradiation levels causes significant intracellular peroxide formation in corneal epithelial cells, and that **lactoferrin** in tears may have a physiological role in protecting the corneal epithelium from solar UV irradiation.

L4 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:612679 CAPLUS
DOCUMENT NUMBER: 125:230803
TITLE: Pharmaceutical and cosmetic compositions containing histamine and interleukin and .alpha.-tumor necrosis factor antagonists
INVENTOR(S): De Lacharriere, Olivier; Breton, Lionel; Cohen, Catherine
PATENT ASSIGNEE(S): Oreal S. A., Fr.
SOURCE: Can. Pat. Appl., 25 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2166179	AA	19960629	CA 1995-2166179	19951227
FR 2728793	A1	19960705	FR 1994-15796	19941228
FR 2728793	B1	19970207		
EP 729750	A1	19960904	EP 1995-402677	19951128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08231432	A2	19960910	JP 1995-341294	19951227
US 5658581	A	19970819	US 1995-580291	19951228
US 5993833	A	19991130	US 1997-879889	19970620

PRIORITY APPLN. INFO.: FR 1994-15796 19941228
US 1995-580291 19951228

AB The title compns. are disclosed. A lotion contained cetrizine 0.001, antioxidants 0.05, isopropanol 40.00, preservatives 0.30, and water q.s. 100%.

```
=> d hist

     (FILE 'HOME' ENTERED AT 09:16:00 ON 01 JUN 2001)

     FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 09:16:15 ON 01 JUN 2001
L1         11130 S LACTOFERRIN
L2        510259 S INFLAMMAT?
L3             5 S ANTIINFLAMMMAT?
L4         97544 S ANTI-INFLAMMAT?
L5           135 S L1 AND L4
L6            64 S L5 AND LACTOFERRIN/TI
L7             9 S L6 AND ANTI-INFLAMMAT?/TI
L8             7 DUPLICATE REMOVE L7 (2 DUPLICATES REMOVED)
L9         54106 S ALLERGEN
L10         5428 S L9 AND L2
L11         1602 S L10 AND ALLERGEN/TI
L12          436 S L11 AND INFLAMMAT?/TI
L13           60 S L12 AND (CLASS? OR TYPE) (S) INFLAMMAT?
L14           32 DUPLICATE REMOVE L13 (28 DUPLICATES REMOVED)
L15            7 S L14 AND PY<=1996
L16            9 S L5 AND ALLERGEN (W) INDUCED
L17            4 DUPLICATE REMOVE L16 (5 DUPLICATES REMOVED)

=> s l1 and l2

L18        1204 L1 AND L2
```

L10 ANSWER 9 OF 11 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 1996:15421 BIOSIS
DOCUMENT NUMBER: PREV199698587556
TITLE: Effects of bovine kappa-casein and **lactoferrins** on several experimental models of **allergic** diseases.
AUTHOR(S): Otani, H.; Yamada, Y.
CORPORATE SOURCE: Lab. Applied Biochemistry Animal Products, Faculty Agriculture, Shinshu Univ., Minamiminowa-mura 399-45, Japan
SOURCE: Milchwissenschaft, (1995) Vol. 50, No. 10, pp. 549-552. CODEN: MILCAD. ISSN: 0026-3788.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 12 Jan 1996
Last Updated on STN: 12 Jan 1996

AB Effects of bovine kappa-casein, **lactoferrin** and peptic **lactoferrin** on vascular permeability, in vitro histamine release, complement-dependent cytolysis, reversed passive Arthus reaction, picryl chloride-induced **contact dermatitis** and delayed-type hypersensitivity were studied using experimental animal models. All proteins tested, ie., kappa-casein, **lactoferrin** and peptic **lactoferrin**, increased the vascular permeability in guinea pigs. kappa-Casein and **lactoferrin** obviously inhibited in vitro histamine release from rat mast cells, whereas peptic **lactoferrin** did not. Moreover, **lactoferrin** inhibited complement-dependent cytolysis to sheep red blood cells (SRBC) in a dose-dependent fashion, whereas kappa-casein and peptic **lactoferrin** had no effect. Arthus reaction, picryl chloride-induced **contact dermatitis** and delayed-type hypersensitivity to SRBC were not modulated by any of these 3 proteins. These results indicate that bovine kappa-casein and **lactoferrin** suppressed a passive cutaneous anaphylactic reaction via inhibiting the vasoactive amine release whereas these same proteins had no effect on the Arthus reaction or delayed-type hypersensitivity.

L4 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1993:131791 CAPLUS
DOCUMENT NUMBER: 118:131791
TITLE: Lipid peroxide formation inhibitors containing **lactoferrin** for cosmetics, food, and pharmaceuticals
INVENTOR(S): Tomono, Norihiro; Chikamatsu, Yoshihiro; Hasebe, Kohei; Inagaki, Masaki; Ando, Yutaka
PATENT ASSIGNEE(S): Ichimaru Pharcos Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04334310	A2	19921120	JP 1991-130662	19910501

AB Lipid peroxide formation inhibitors contg. **lactoferrin** as an active ingredient are claimed. Bovine **lactoferrin** at 0.1% showed 100% inhibition on **UV-induced** peroxidn. of linoleic acid. A peel-off pack contg. H2O 66.5, glycerin 5.0, propylene glycol 4.0, poly(vinyl alc.) 15.0, EtOH 8.0, polyoxyethylene glycol 1.0, p-HOC6H4CO2Me 0.2, perfume 0.2, and **lactoferrin** 0.1 wt.% was prepd.

L8 ANSWER 6 OF 7 MEDLINE DUPLICATE 1

ACCESSION NUMBER: 96001603 MEDLINE

DOCUMENT NUMBER: 96001603 PubMed ID: 8526014

TITLE: **Anti-inflammatory** capacities of human milk: **lactoferrin** and secretory IgA inhibit endotoxin-induced cytokine release.

AUTHOR: Hanson L A; Mattsby-Baltzer I; Engberg I; Roseanu A; Elverfors J; Motas C

CORPORATE SOURCE: Department of Clinical Immunology, University of Goteborg, Sweden.

SOURCE: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, (1995) 371A 669-72.
Journal code: 2LU; 0121103. ISSN: 0065-2598.

PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199601

ENTRY DATE: Entered STN: 19960219
Last Updated on STN: 19970203
Entered Medline: 19960124

L8 ANSWER 7 OF 7 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 95282643 MEDLINE
DOCUMENT NUMBER: 95282643 PubMed ID: 7762426
TITLE: The role of **lactoferrin** as an **anti-inflammatory** molecule.
AUTHOR: Britigan B E; Serody J S; Cohen M S
CORPORATE SOURCE: Department of Internal Medicine, VA Medical Center, Iowa City, Iowa, USA.
CONTRACT NUMBER: AI28412 (NIAID)
AI92959 (NIAID)
HL44275 (NHLBI)
SOURCE: ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, (1994) 357 143-56. Ref: 102
Journal code: 2LU; 0121103. ISSN: 0065-2598.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199506
ENTRY DATE: Entered STN: 19950707
Last Updated on STN: 20000303
Entered Medline: 19950623

AB The formation of hydroxyl radical via the iron catalyzed Haber-Weiss reaction has been implicated in phagocyte-mediated microbicidal activity and inflammatory tissue injury. The fact that neutrophils contain **lactoferrin** and mononuclear phagocytes have the capacity to acquire exogenous iron has suggested that iron bound to **lactoferrin** may influence the nature of free radical products generated by these cells. Over the years the iron-**lactoferrin** complex has been heralded as both a promoter and inhibitor of hydroxyl radical formation. This manuscript is intended to provide an overview of work performed to date related to this controversy and to present results of a number of preliminary studies which shed further light on the role of **lactoferrin** in inflammation.

ANSWER 3 OF 7 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:382957 CAPLUS
DOCUMENT NUMBER: 134:40716
TITLE: **Anti-inflammatory** and immunoregulatory properties of **lactoferrin**
AUTHOR(S): Brock, Jeremy H.; Guillen, Cristina; Thompson, Claire
CORPORATE SOURCE: Department of Immunology and Bacteriology, University of Glasgow, Western Infirmary, Glasgow, G11 6NT, UK
SOURCE: Int. Congr. Ser. (2000), 1195(Lactoferrin: Structure, Function and Applications), 119-128
CODEN: EXMDA4; ISSN: 0531-5131
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 59 refs. A variety of **anti-inflammatory** and immunomodulatory effects have been reported for **lactoferrin**. These include binding of free iron at sites of local inflammation, modulation of T and B lymphocyte proliferation and maturation, regulation of NK cell activity, and modulation of cytokine prodn. These are related here to the biochem. properties of **lactoferrin**, in particular, its ability to bind iron and to interact with other mols. and cell surfaces. The regulation of **lactoferrin** synthesis and release by neutrophils is discussed. Also, the occurrence of anti-**lactoferrin** autoantibodies is discussed, as well as the effect of antibodies on the iron-binding properties of **lactoferrin**. At physiol. pH (7.4) antibodies prevent iron binding but do not release iron already bound. In contrast, at pH 5 antibodies induce release of iron from **lactoferrin**. Thus, antibodies may interfere with the ability of **lactoferrin** to sequester potentially toxic free iron at sites of inflammation.

REFERENCE COUNT: 59
REFERENCE(S):
(1) Afeltra, A; Clin Exp Immunol 1997, V109, P279 CAPLUS
(2) Afeltra, A; Endocrine Res 1998, V24, P185 CAPLUS
(4) Brock, J; Adv Exp Biol Med 1998, V443, P305 CAPLUS
(5) Brock, J; Immunol Today 1995, V16, P417 CAPLUS
(6) Brock, J; J Nutr Immunol 1993, V2, P47 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
L5 and lactoferrin.clm.	43

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L6

Refine Search

Recall Text | Clear

Search History

DATE: Tuesday, October 28, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB; PLUR=YES; OP=AND			
L6	L5 and lactoferrin.clm.	43	L6
L5	L3	297	L5
DB=JPAB,EPAB,DWPI; PLUR=YES; OP=AND			
L4	L3	13	L4
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=AND			
L3	L2 and (asthma or diaper adj rash or contact adj dermatitis or uv adj induced adj inflammat$ or psoriasis or arthritis)	310	L3
L2	lactoferrin	2134	L2
DB=USPT; PLUR=YES; OP=AND			
L1	lactoferrin	855	L1

END OF SEARCH HISTORY

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Terms	Documents
L9 and l2	3

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L10

Refine Search

Recall Text | Clear

Search History

DATE: Thursday, February 28, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=AND			
L10	L9 and l2	3	L10
L9	Interleukin-1 adj antagonist$	61	L9
L8	Interleukin-1 adj antagonists	61	L8
L7	L6 and l2	18	L7
L6	asthma	27921	L6
L5	L4 and l2	22	L5
L4	L3 and allergen	1499	L4
L3	inflammat$ or antiinflammat$	105086	L3
L2	lactoferrin$	1377	L2
L1	2596986 or 2641696	34	L1

END OF SEARCH HISTORY